血浆尿酸、肺功能与慢阻肺的孟德尔随机化研究
基于哥本哈根心脏研究(Copenhagen City Heart Study)与哥本哈根一般人群研究(Copenhagen General Population Study)共114 979人的数据,观察性分析显示血浆尿酸每升高100 µmol/L与FEV1占预计值百分比下降1.54%、FVC占预计值百分比下降1.57%相关,COPD的OR为1.08;但以SLC2A9 rs7442295和ABCG2 rs2231142进行的遗传因果分析未显示相关,不支持直接因果关系。
要点
- 观察性分析中高血浆尿酸与肺功能更差及COPD风险升高相关。
- 遗传决定的血浆尿酸与肺功能、呼吸道症状及COPD均无显著关联。
- 数据不支持血浆尿酸对肺功能或COPD存在直接因果作用。
核心结论
- 观察性分析中高血浆尿酸与更差肺功能及更高呼吸道症状和COPD风险相关,但遗传决定的高血浆尿酸与这些结局均无关,数据不支持直接因果关系。
研究设计与样本
- 研究在哥本哈根心脏研究与哥本哈根一般人群研究中进行,共纳入114 979人测量肺功能与血浆尿酸。
- 对110 152人检测SLC2A9 rs7442295与ABCG2 rs2231142两个与高血浆尿酸相关的基因变异。
- 采用孟德尔随机化方法比较观察性与遗传决定的血浆尿酸与肺功能、呼吸道症状及COPD的关联。
主要发现
- 观察性分析中,血浆尿酸每升高100 µmol/L,FEV1占预计值百分比低1.54%(95%CI -1.67至-1.40),FVC占预计值百分比低1.57%(95%CI -1.69至-1.44)。
- 遗传决定的血浆尿酸每升高100 µmol/L,FEV1占预计值百分比变化为-0.46%(95%CI -1.17至0.25),FVC占预计值百分比变化为-0.40%(95%CI -1.03至0.23)。
- 观察性分析中高血浆尿酸与呼吸道症状风险升高相关,但遗传决定的高血浆尿酸与呼吸道症状无关。
- 共识别14 151例COPD,观察性分析每100 µmol/L血浆尿酸的OR为1.08(95%CI 1.06至1.11),遗传分析OR为1.01(95%CI 0.88至1.15)。
临床怎么用
- 提示临床观察到的尿酸与肺功能、COPD的关联可能受混杂因素影响,不宜据此将降尿酸作为改善肺功能或预防COPD的干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Urate is a strong antioxidant in plasma and may protect against lung function impairment. We tested the hypothesis that high plasma urate is causally associated with better lung function and low risk of respiratory symptoms and COPD. METHODS: We measured lung function and plasma urate in 114 979 individuals from the Copenhagen City Heart Study and the Copenhagen General Population Study and genotyped for SLC2A9 rs7442295 and ABCG2 rs2231142 variants, previously associated with high plasma urate, in 110 152 individuals. RESULTS: In the two studies combined, multivariable-adjusted 100 µmol/L higher plasma urate was associated with -1.54% (95% CI -1.67 to -1.40) lower FEV1 % predicted and -1.57% (95% CI -1.69 to -1.44) lower FVC % predicted observationally; the corresponding estimates for genetically determined 100 µmol/L higher plasma urate were -0.46% (95% CI -1.17 to 0.25) and -0.40% (95% CI -1.03 to 0.23). High plasma urate was also associated with higher risk of respiratory symptoms; however, genetically determined high plasma urate was not associated with respiratory symptoms. Finally, we identified 14 151 individuals with COPD and found ORs of 1.08 (95% CI 1.06 to 1.11) for COPD observationally and 1.01 (95% CI 0.88 to 1.15) genetically per 100 µmol/L higher plasma urate. CONCLUSION: High plasma urate was associated with worse lung function and higher risk of respiratory symptoms and COPD in observational analyses; however, genetically high plasma urate was not associated with any of these outcomes. Thus, our data do not support a direct causal relationship.
引用
- Kobylecki CJ, Vedel-Krogh S, Afzal S, et al. Plasma urate, lung function and chronic obstructive pulmonary disease: a Mendelian randomisation study in 114 979 individuals from the general population. Thorax. 2017. PMID: 29187594. doi:10.1136/thoraxjnl-2017-210273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。